Details for New Drug Application (NDA): 210701
✉ Email this page to a colleague
NDA 210701 describes AMBRISENTAN, which is a drug marketed by Apotex, Aurobindo Pharma, Cipla, Endo Operations, Mylan, Sigmapharm Labs Llc, Sun Pharm, Watson Labs Inc, and Zydus Pharms, and is included in nine NDAs. It is available from ten suppliers. Additional details are available on the AMBRISENTAN profile page.
The generic ingredient in AMBRISENTAN is ambrisentan. There are nine drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the ambrisentan profile page.
The generic ingredient in AMBRISENTAN is ambrisentan. There are nine drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the ambrisentan profile page.
Summary for 210701
| Tradename: | AMBRISENTAN |
| Applicant: | Apotex |
| Ingredient: | ambrisentan |
| Patents: | 0 |
Pharmacology for NDA: 210701
| Mechanism of Action | Endothelin Receptor Antagonists |
Suppliers and Packaging for NDA: 210701
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| AMBRISENTAN | ambrisentan | TABLET;ORAL | 210701 | ANDA | Apotex Corp. | 60505-4552 | 60505-4552-3 | 30 TABLET, FILM COATED in 1 BOTTLE (60505-4552-3) |
| AMBRISENTAN | ambrisentan | TABLET;ORAL | 210701 | ANDA | Apotex Corp. | 60505-4553 | 60505-4553-3 | 30 TABLET, FILM COATED in 1 BOTTLE (60505-4553-3) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 5MG | ||||
| Approval Date: | May 19, 2022 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 10MG | ||||
| Approval Date: | May 19, 2022 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
